Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 24, 2006. The document serves as a notification of transactions involving Persons Discharging Managerial Responsibility (PDMRs) in the company's Ordinary Shares and American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share transaction details.
- Ordinary Share Sale Price: GBP 14.65 per share.
- ADS Sale Price: $51.3499 per ADS.
- Transaction Date: February 23, 2006.
Material Changes
The filing details changes in shareholdings for specific executives arising from the sale of shares to meet tax liabilities following the vesting of a Performance Share Plan award. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to Disclosure Rule 3.1.4R(1)(a) regarding director and executive transactions.
Important Facts for Investors
- Transactions were executed on February 23, 2006, specifically to satisfy tax obligations related to vesting Performance Share Plan awards.
- Ordinary Shares were sold by seven individuals, including Mr. R Bondy (6,150 shares) and Mr. C Viehbacher (4,868 shares).
- American Depositary Shares (ADSs) were sold by two individuals: Dr. F Calhoun (1,670 ADSs) and Dr. R Greig (500 ADSs).
- The Company Secretary, S M Bicknell, confirmed the company was advised of these transactions on February 23, 2006.